These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 9303825)

  • 1. [Injectable phenytoin: problems of stability in solution].
    Francés A; García Martí A; Bruck M
    Bull Soc Sci Med Grand Duche Luxemb; 1997; 134(1):9-12. PubMed ID: 9303825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenytoin sodium solubility in three intravenous solutions.
    Pfeifle CE; Adler DS; Gannaway WL
    Am J Hosp Pharm; 1981 Mar; 38(3):358-62. PubMed ID: 7223749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compatibility and pH variability of four injectable phenytoin sodium products.
    Markowsky SJ; Kohls PR; Ehresman D; Leppik I
    Am J Hosp Pharm; 1991 Mar; 48(3):510-4. PubMed ID: 2028998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation and in vitro and in vivo characterization of a phenytoin self-emulsifying drug delivery system (SEDDS).
    Atef E; Belmonte AA
    Eur J Pharm Sci; 2008 Nov; 35(4):257-63. PubMed ID: 18706499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buffer capacity and precipitation control of pH solubilized phenytoin formulations.
    Alvarez-Núñez FA; Yalkowsky SH
    Int J Pharm; 1999 Aug; 185(1):45-9. PubMed ID: 10425364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phenytoin and phenytoin derivatives for local administration].
    Fürst W; Wildner R
    Pharmazie; 1991 Jun; 46(6):424-6. PubMed ID: 1763120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of a practical guide for utilization of injectable drugs in neonatology and in pediatrics].
    Veillet B; Courrege C; Poujol H; Kinowski JM; Bressolle F
    Therapie; 1996; 51(4):403-9. PubMed ID: 8953817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of compressed gas precipitation to enhance the dissolution behavior of a poorly water-soluble drug: generation of drug microparticles and drug-polymer solid dispersions.
    Muhrer G; Meier U; Fusaro F; Albano S; Mazzotti M
    Int J Pharm; 2006 Feb; 308(1-2):69-83. PubMed ID: 16324806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 5% glucose infusion fluid provokes significant precipitation of phenytoin sodium injection via interruption of the cosolvent effect of propylene glycol.
    Onuki Y; Ikegami-Kawai M; Ishitsuka K; Hayashi Y; Takayama K
    Chem Pharm Bull (Tokyo); 2012; 60(1):86-93. PubMed ID: 22223379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of phenytoin solubility in intravenous admixtures: physicochemical theory.
    Newton DW; Kluza RB
    Am J Hosp Pharm; 1980 Dec; 37(12):1647-51. PubMed ID: 7446539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Micronization of phenytoin by precipitation].
    Dobrucki R; Wojciechowska A
    Acta Pol Pharm; 1992; 49(1-2):103-7. PubMed ID: 8769084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenytoin-loading: pharmacokinetic comparison between an intravenous bolus injection and a diluted standard solution.
    Andersen BB; Møller A; Gram L; Jensen NO; Dam M
    Acta Neurol Scand; 1992 Mar; 85(3):174-6. PubMed ID: 1574998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of drug precipitation upon dilution of pH-controlled formulations.
    Narazaki R; Sanghvi R; Yalkowsky SH
    Mol Pharm; 2007; 4(4):550-5. PubMed ID: 17530775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studying long-term effect of phenytoin either alone or combined with ascorbic acid on the anesthetic effect of urethane in rats.
    El Desoky ES; Abdulla MM
    Fundam Clin Pharmacol; 2004 Apr; 18(2):153-6. PubMed ID: 15066128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma compatibility of injectables: comparison of intravenous U-74006F, a 21-aminosteroid antioxidant, with Dilantin brand of parenteral phenytoin.
    Cox JW; Sage GP; Wynalda MA; Ulrich RG; Larson PG; Su CC
    J Pharm Sci; 1991 Apr; 80(4):371-5. PubMed ID: 1865339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formation of phenytoin nanoparticles using rapid expansion of supercritical solution with solid cosolvent (RESS-SC) process.
    Thakur R; Gupta RB
    Int J Pharm; 2006 Feb; 308(1-2):190-9. PubMed ID: 16352406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of phenytoin and its metabolite, 4'-HPPH, after intravenous and oral administration of phenytoin to diabetic rats induced by alloxan or streptozotocin.
    Kim YC; Kang HE; Lee MG
    Biopharm Drug Dispos; 2008 Jan; 29(1):51-61. PubMed ID: 18022993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual compatibility of premixed theophylline or heparin with selected drugs for i.v. administration.
    Kershaw BP; Monnier HL; Mason JH
    Am J Hosp Pharm; 1993 Jul; 50(7):1360, 1362-3. PubMed ID: 8362868
    [No Abstract]   [Full Text] [Related]  

  • 20. Fosphenytoin.
    Eriksson K; Keränen T; Kälviäinen R
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):695-701. PubMed ID: 19473113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.